Anti-smoking drugs may increase risk of depression
-Examiner
07/14/2009 - Psychiatric issues in patients using anti-smoking drugs has led the Food and Drug Administration to call for the agency’s strongest warning, a “Black Box” warning. Chantix, a smoking cessation drug made by Pfizer, Inc., and Zyban, a product of GlaxoSmithKline PLC, are to undergo additional testing and studies to more accurately rate the possibility of depression and suicidal thoughts occurring while taking the drugs for the purpose of quitting smoking.
Regardless of these possible side effects, however, the benefits may outweigh the risks. Smoking can lead to various cancers, stroke, heart attack, emphysema, and pulmonary disease. Smokers and their doctors should look at the health benefits of using a smoking cessation drug, taking into account previous psychiatric problems. Currently, Chantix has a warning against driving or operating heavy machinery, as well as a ban on use by air traffic controllers and airline pilots. These warning were the result of previous reports of injuries due to blackouts. If you are currently taking Chantix and have concerns about its safety, you should consult with your doctor regarding your treatment options. Under no circumstances should you discontinue taking any medication, including Chantix, without first consulting with your doctor. For Chantix legal information contact the Chantix Attorneys of Ennis & Ennis, P.A. by filling out our free Chantix case evaluation form or by calling the toll-free number listed below.
|